Search

Your search keyword '"Cecco, L. De"' showing total 12 results
Start Over Author "Cecco, L. De"
12 results on '"Cecco, L. De"'

1. Development of a Multiomics Database for Personalized Prognostic Forecasting in Head and Neck Cancer: The Big Data to Decide EU Project

Author

Cavalieri, Stefano, Cecco, L. de, Brakenhoff, R.H., Serafini, M.S., Canevari, S., Rossi, S., Lanfranco, D., Hoebers, F.J.P., Wesseling, F.W.R., Keek, S., Scheckenbach, K., Mattavelli, D., Hoffmann, T., López Pérez, L., Fico, G., Bologna, M., Nauta, I., Leemans, C.R., Trama, A., Klausch, T., Berkhof, J.H., Tountopoulos, V., Shefi, R., Mainardi, L., Mercalli, F., Poli, T., Licitra, L., Wesarg, S., and Publica

Subjects
Lead Topic: Individual Health, Research Line: Modeling (MOD), Research Line: Machine Learning (ML), Big Data, patient model, oral cancer
Abstract

Background Despite advances in treatments, 30% to 50% of stage III-IV head and neck squamous cell carcinoma (HNSCC) patients relapse within 2 years after treatment. The Big Data to Decide (BD2Decide) project aimed to build a database for prognostic prediction modeling. Methods Stage III-IV HNSCC patients with locoregionally advanced HNSCC treated with curative intent (1537) were included. Whole transcriptomics and radiomics analyses were performed using pretreatment tumor samples and computed tomography/magnetic resonance imaging scans, respectively. Results The entire cohort was composed of 71% male (1097)and 29% female (440): oral cavity (429, 28%), oropharynx (624, 41%), larynx (314, 20%), and hypopharynx (170, 11%); median follow-up 50.5 months. Transcriptomics and imaging data were available for 1284 (83%) and 1239 (80%) cases, respectively; 1047 (68%) patients shared both. Conclusions This annotated database represents the HNSCC largest available repository and will enable to develop/validate a decision support system integrating multiscale data to explore through classical and machine learning models their prognostic role.

Published
2021

2. Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment

Author

Tazzari, M., Indio, V., Vergani, B., Cecco, L. De, Rini, F., Negri, T., Camisaschi, C., Fiore, M., Stacchiotti, S., Dagrada, G.P., Casali, P.G., Gronchi, A., Astolfi, A., Pantaleo, M.A., Villa, A., Lombardo, C., Arienti, F., Pilotti, S., Rivoltini, L., Castelli, C., Tazzari, M., Indio, V., Vergani, B., Cecco, L. De, Rini, F., Negri, T., Camisaschi, C., Fiore, M., Stacchiotti, S., Dagrada, G.P., Casali, P.G., Gronchi, A., Astolfi, A., Pantaleo, M.A., Villa, A., Lombardo, C., Arienti, F., Pilotti, S., Rivoltini, L., and Castelli, C.

Abstract

Item does not contain fulltext, Dermatofibrosarcoma protuberans (DFSP), although rare, is the most frequent skin sarcoma. Here, we focus on DFSP carrying the fibrosarcomatous transformation (FS-DFSP). FS-DFSP responds to imatinib (IM); however, tumor relapse often occurs. In a series of 21 pre- and post-treatment FS-DFSP samples, the present study explored the events that occur at the tumor site during IM therapy. Gene expression profile and immunohistochemistry analyses documented the occurrence of IM-induced senescence phenotype in the tumor cells and showed the accumulation of activated CD3+ T cells and CD163+CD14+ myeloid cells expressing the CD209 marker in post-therapy lesions. In post-IM specimens, the pathological response and tumor apoptosis were tightly associated with T-cell infiltration, thus suggesting the presence of an ongoing anti-tumor response, which was further confirmed by in vitro functional assays with CD3+ T cells isolated from an IM-responding FS-DFSP lesion. The integration of targeted therapies with immune therapies is currently under investigation to achieve longer tumor control. Our data outline the in situ immunological effects of IM and classify IM-treated FS-DFSP as potentially sensitive to immunotherapy, thus providing the rationale for further investigations of combination treatment for this soft-tissue sarcoma.

Published
2017

10. 103P Comparative study of RT-qPCR- and NGS- based platforms for circulating human microRNA biomarker detection.

Author

Gargiuli, C, Dugo, M, Cecco, L De, Iannò, M F, Mariancini, A, Marchesi, E, Mancinelli, E, Micali, A, Boeri, M, Sozzi, G, and Sensi, M

Subjects
*MICRORNA, *COMPARATIVE studies, *PLASMA focus, *LUNG cancer, *RNA
Abstract

Background Circulating microRNAs (cmiRNAs) are emerging as promising non-invasive biomarkers in cancer for their diagnostic, prognostic and predictive potential. Several platforms have been developed to determine the presence of miRNAs in biological fluids, including specific focus panels. In this pilot study, we aimed at comparing different platforms for detection of cmiRNAs against the same cohort of plasma samples alongside RT-qPCR and NGS technologies. Methods RNA was isolated from 24 plasma samples obtained from lung cancer patients (n = 12, including one replicate) and healthy heavy smokers (n = 12, including two replicates). Six different platforms were used to detect human cmiRNAs. Five of them were high-throughput technologies, three RT-qPCR-based (TaqMan OpenArray and TaqMan OpenArray Advanced MicroRNA Panels by ThermoFisher; miRCURY LNA miRNA miRNome PCR panel by Qiagen) and two NGS-based (EdgeSeq miRNA byHTG and QiaSeq miRNA by Qiagen). The sixth platform, RT-qPCR-based and serum/plasma focused, was TaqMan Advanced miRNA Human Card by ThermoFisher. Samples were handled according to manufacturer's instructions and data from each platform were analyzed using specific recommended thresholds. Results Selecting cmiRNAs yielding signals above background, we highlighted a subset commonly detected by all platforms. Strong concordance and correlation coefficients (>0.8) between the three replicate samples were obtained in most platforms, from independent RNA extractions. For each sample, the number of cmiRNAs detected ranged from 90 to 140. We found that inter-platform correlations were highest for platforms based on similar chemistry and assay design. Between lung cancer patients and healthy donors, few deregulated miRNAs could be however commonly detected by all platforms and studies are ongoing to elucidate their role. Conclusions This study is one of the first comparing RT-qPCR, NGS-based high-throughput and serum/plasma focused platforms for human cmiRNA biomarker detection. Advantages and limits of all platforms and data on intra- and inter- reproducibility will be presented to help investigators in identifying technologies better suited for cmiRNAs screening or validation in clinical cohorts. Legal entity responsible for the study The authors. Funding Italian Association for Cancer Research (AIRC, Special Programme "5 X 1000", ED No12162) to GS and MS and by Italian Ministry of Health (funds obtained through an Italian law that allows tax-payers to allocate the "5 × 1000" share of their payments to research) to LDC. Disclosure All authors have declared no conflicts of interest. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results